compound
Tirzepatide (30mg Vial) Questions Answered
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2] .
Tirzepatide (30mg Vial)
Phase Weekly Dose (mg) Units (per injection) (mL) Weeks 1–4 2.5 mg 25 units (0.25 mL) × 1 injection Weeks 5–8 5 mg 50 units (0.50 mL) × 1 injection Weeks 9–12 7.5 mg 75 units (0.75 mL) × 1 injection Weeks 13–16 10 mg 100 units (1.0 mL) × 1 injection Frequen...
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2] .
Phase Weekly Dose (mg) Units (per injection) (mL) Weeks 1–4 2.5 mg 25 units (0.25 mL) × 1 injection Weeks 5–8 5 mg 50 units (0.50 mL) × 1 injection Weeks 9–12 7.5 mg 75 units (0.75 mL) × 1 injection Weeks 13–16 10 mg 100 units (1.0 mL) × 1 injection Frequen...
Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing). Peptide Vials (Tirzepatide, 30 mg each): 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 1 vial 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 2 vials 16 weeks (2.5→10 mg/wk): ~100 mg total ≈...
Proper storage preserves peptide quality. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.